GO
Loading...

Enter multiple symbols separated by commas

FDA Approves GlaxoSmithKline's Oral Drug for Breast Cancer

U.S. health regulators have approved GlaxoSmithKline'spill, Tykerb, for patients with advanced breast cancer after other treatments have failed, the company said on Tuesday.

The drug was cleared for once-daily use in combination with Roche Holding'soral chemotherapy drug Xeloda, or capecitabine, Glaxo said.

Glaxo shares recovered earlier losses after the late afternoon news and closed down 75 cents at $55.25 on the New York Stock Exchange.

Tykerb's approval is expected to launch what Glaxo hopes will be a new era for its oncology business, which is looking to win U.S. clearance for four other cancer medications by 2010.

The Food and Drug Administration approved the drug, also known as lapatinib, for patients with HER-2 positive breast cancer who no longer respond to Roche and Genentech rival product, Herceptin.

Patients should have also tried anthracycline and taxane chemotherapy drugs such as Sanofi-Aventis's, Taxotere, or Bristol-Myers Squibb's, Taxol, the agency added.

Those with the HER-2 positive disease face a more aggressive cancer in which the human epidermal growth factor receptor 2 is over-expressed.

Some analysts expect Glaxo's drug to bring in yearly sales of about $1.35 billion, by 2010. If it were to win approval for more uses, that figure could jump as high as $4 billion a year, according to some estimates.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • Why women cheat?

    Is cheating bad? Why do women cheat? The founder and CEO of affair website Ashley Madison tells all, including why he has his eye on China.

  • American Pharoah

    As American Pharoah chases the Triple Crown at the Preakness this Saturday, his earning potential can only go up.

  • Banking on your brand: Mika Brezezinski

    Mika Brezezinski, "Morning Joe" co-host, talks about giving women, entrepreneurs and millennials the tools to live and work to their full potential.

U.S. Video

  • Cramer: Here's a sign the market could rally

    Wall Street's been soaking in red, but "Mad Money" host Jim Cramer has one signal to watch for that could point to another run.

  • Burger war maneuvers

    Cramer looks at the number of company's selling burgers and tries to determine the quality names, as well as those to avoid.

  • Cramer: What's driving defense?

    Cramer says that even though President Obama has made it clear the US can no longer be the world's policeman, the country can become the world's arms dealer. Profiting from defense spending.